Intrahospital switch of the P2Y12 inhibitors in patients with ST segment elevation myocardial infarction in ‘real-life’ clinical practice: the effect on the functional activity of thrombocytes and thrombocytopoiesis, prognostic value

Aim. To assess the P2Y₁₂ inhibitors switch in patients ST segment elevation myocardial infarction (STEMI) in real-life’ clinical practice, evaluate the functional activity of thrombocytes and thrombocytopoiesis and determine the clinical and prognostic value of P2Y₁₂ inhibitors switch in the framework of dual antiplatelet therapy in patients with STEMI.

Material and methods. We conducted local, stratified, prospective study in which were involved 101 patients, hospitalized no later than 12hours after the STEMI manifestation. The antiplatelet therapy (APT), prescribed by the physicians at the pre-hospital and inpatient phases of treatment, was analyzed. Functional activity of thrombocytes, levels of thrombopoietin (THPO), stromal cell-derived factor 1 (SDF1) and thrombopoietic receptor (MPL) were investigated. The minimum observation period was 2 years. Death and repeated hospitalizations due to cardiovascular causes were monitored.

Results. P2Y₁₂ inhibitors were switched in 32,7% of patients with STEMI. In the hospital, clopidogrel, which was prescribed at the prehospital phase, was replaced with ticagrelor (early APT escalation) — 22,8%. Patients with early APT escalation by the seventh day had significantly greater inhibition of platelet aggregation activity parameters (slope of the aggregation curve, latent aggregation time and area under the aggregation curve). Activation of the collagen-induced platelet aggregation was detected. With the early escalation of APT, the THPO level was statistically significantly higher, both on the second and on the 7th day measurements: 256,2 (209,0; 396,8) pg/ml vs 137,5 (105,7; 179,1) pg/ml (p=0,000) and 283,4 (228,9; 334,3) pg/ml vs 226,5 (163,2; 287,3) pg/ml (p=0,045), respectively. The frequency of reaching the combined endpoint (death + re-hospitalization) was 7,9% in patients who had a P2Y12 switch, and 28,1% in patients who did not change the P2Y₁₂ blocker.

Conclusion. In actual clinical practice, patients with STEMI had the most frequent early APT escalation, which was characterized by a more significant suppression of adenosine diphosphate-induced platelet aggregation and secretion than in patients without P2Y₁₂ inhibitors switch, but with activation of collagen-induced aggregation. An increase in thrombocytogenesis was revealed in early replacement of clopidogrel by ticagrelor. Intrahospital replacement of the P2Y₁₂ inhibitor in patients with STEMI was accompanied by a decrease in the two-year death risk and repeated hospitalizations.

1. Ruda MJ, Averkov OB, Komarov AL, et al. On the possibilities of weakening the 9. intensity of antiplatelet therapy in patients after acute coronary syndrome resolving the information of experts on emergency cardiology. Emergency cardiology. 2017;44-5. (In Russ.)

2. Angiolillo DJ, Rollini F, Storey RF, et al. International Expert Consensus on Switching Platelet P2Yi2 Receptor-Inhibiting Therapies. Circulation. 2017;136:1955-75. doi:10.1161/CIRCULATIONAHA.118.033779.

3. Naziroglu, M. TRPM2 channel membrane currents in primary rat megakaryocytes were activated by the agonist ADP-ribose but not oxidative stress. J Membr Biol. 2011 May;241(2):51-7. doi:10.1007/s00232-011-9356-8.

4. Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationThe Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017:ehx393-ehx393. doi:10.1093/eurheartj/ehx393.

5. Alexopoulos D, Xanthopoulou I, Deftereos S, et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J. 2014;167:68-76 e2. doi:10.1016/j.ahj.2013.10.010.

6. Biscaglia S, Campo G, Pavasini R, et al. Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. Platelets. 2016;27:484-7. doi:10.3109/09537104.2015.1119815.

7. Wang X, Xi S, Liu J, et al. Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients. European heart journal supplements. J Eur Society of Cardiology. 2016;18:F19-26. doi:10.1093/eurheartj/suw034.

8. De Luca L, D'Ascenzo F, Musumeci G, et al. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention. 2017;13:459-66. doi:10.4244/EIJ-D-17-00092.

9. Oganov PG, Lepakhin VK, Fitilev SB, et al. Assessing the implementation of the recommendations on secondary cardiovascular prevention in patients after myocardial infarction (a pharmaco-epidemiologic study). Cardiovascular Therapy and Prevention. 2009;8(4):71-5. (In Russ.)

10. Rollini F, Franchi F, Angiolillo DJ. Switching P2Y!2-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol. 2016;13:11-27. doi: 10.1038/nrcardio.2015.113.

11. Rollini F, Franchi F, Cho JR, et al. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J. 2016;37:2722-30. doi:10.1093/eurheartj/ehv744.

12. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188-99. doi:10.1161/CIRCULATIONAHA.109.919456.

13. Tavlueva EB, Yarkovskaya AP, Alekseenko AV, et al. Hypoaggregatory effect in patients with myocardial infarction with the rise of the segment st when replacing clopidogrel with ticagrelor. Atherothrombosis. 2016;54-60. (In Russ.)

14. Malinova L, Furman N, Dolotovskaya P, et al. Thrombopoeitin as a biomarker and a regulatory mediator in acute heart failure. Eur J Heart Failure. 2018;20:112. doi:10.1002/ejhf.1197.

15. Nosovsky AM, Pihlak AE, Logachev VA, et al. Statistics of small samples in medical research. Russian Medical Journal 2013: 57-60. (In Russ.)